Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

PORTAGE BIOTECH INC. (BNTNF) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Form of Pre-Funded Ordinary Share Purchase Warrant",
"Form of Series A Ordinary Share Purchase Warrant",
"Form of Series B Ordinary Share Purchase Warrant",
"Form of Series C Ordinary Share Purchase Warrant",
"Form of Placement Agent Ordinary Share Purchase Warrant",
"Opinion of Forbes Hare LLP",
"Opinion of Hogan Lovells US LLP",
"Form of Securities Purchase Agreement, by and between Portage Biotech Inc. and the Purchaser signatory thereto"
10/02/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/29/2023 6-K Quarterly results
08/14/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Corporate Presentation"
07/31/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
05/01/2023 6-K Quarterly results
03/01/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Unaudited Condensed Consolidated Interim Financial Statements for the three and nine months ended December 31, 2022. Unaudited - Prepared by Management as of March 1, 2023",
"Management’s Discussion and Analysis for the three and nine months ended December 31, 2022"
01/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Corporate Presentation"
11/30/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Corporate Presentation"
11/29/2022 6-K Quarterly results
11/15/2022 6-K Quarterly results
11/09/2022 6-K Quarterly results
10/07/2022 6-K Quarterly results
09/22/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Form of updated Articles of Association as of September 20, 2022"
09/14/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Corporate Presentation"
08/29/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Unaudited Condensed Consolidated Interim Financial Statements for the three months ended June 30, 2022. Unaudited - Prepared by Management as of August 29, 2022",
"Management’s Discussion and Analysis for the three months ended June 30, 2022"
08/19/2022 6-K Quarterly results
08/19/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/01/2022 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
08/01/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022"
07/29/2022 D Form D - Notice of Exempt Offering of Securities:
07/19/2022 6-K Quarterly results
07/08/2022 6-K Quarterly results
07/07/2022 6-K Quarterly results
06/23/2022 6-K Quarterly results
03/31/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Press Release"
03/03/2022 20-F/A Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
02/25/2022 6-K Quarterly results
02/24/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"PORTAGE BIOTECH INC. Consolidated Statements of Financial Position As of, December 31, 2021 March 31, 2021"
02/15/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Press Release"
11/23/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"The accompanying notes are an integral part of these condensed consolidated interim financial statements. F-2 Portage Biotech Inc. Condensed Consolidated Interim Statements of Operations and Other Comprehensive Note Three months ended September 30, Six months ended September 30, 2021 2020 2021 2020 In 000’$ In 000’$ In 000’$ In 000’$ Expenses Research and development $ 1,330 $ 792 $ 2,876 $ 1,244 General and administrative expenses 2,000 376 4,047 897 Loss from operations Change in fair value of warrant liability 13 15 59 384 59 Share of income in associate accounted for using equity method 7 391 on equity issued at a discount 14 – – Gain on sale of marketable equity securities 6 – 72 – 72 on extinguishment of notes payable 12 – – Interest Loss before provision for income taxes Inc...",
"PORTAGE BIOTECH INC. THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2021 MANAGEMENT’ S DISCUSSION AND ANALYSIS Prepared as of November 23, 2021 Index Forward-Looking Statements 3 Nature of Operations and Overview 4 Summary of Results 8 Number of Ordinary Shares and Options 8 Business Environment - Risk Factors 8 Our Programs and Technology - Recent Developments 9 Results of Operations 12 Liquidity and Capital Resources 16 Key Contractual Obligations 18 Off-balance Sheet Arrangements 18 Transactions with Related Parties 18 Financial and Derivative Instruments 19 Use of Estimates and Judgments 21 New Accounting Standards, Interpretations and Amendments 21 Internal Controls over Financial Reporting 21 Public Securities Filings 22 2 Management Discussion and Analysis"
11/23/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"PORTAGE BIOTECH INC. Consolidated Statements of Operations and Comprehensive Income Note Three months ended September 30, Six months ended September 30, 2021 2020 2021 2020 In 000’$ In 000’$ In 000’$ In 000’$ Expenses Research and development $ 1,330 $ 792 $ 2,876 $ 1,244 General and administrative expenses 2,000 376 4,047 897 Loss from operations Change in fair value of warrant liability 13 15 59 384 59 Share of income in associate accounted for using equity method 7 391 on equity issued at a discount 14 – – Gain on sale of marketable equity securities 6 – 72 – 72 on extinguishment of notes payable 12 – – Interest Loss before provision for income taxes Income tax benefit 503 – 582 – Net Other comprehensive income Unrealized on investment 6, 9 – – – Total comprehensive for period..."
08/30/2021 6-K Quarterly results
08/30/2021 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy